LAG3 and hepatocellular carcinoma: In this context, the phase II study RELATIVITY-073 is exploring the combination of relatlimab (the first-in-class anti-LAG3 mAb) with nivolumab in patients with advanced HCC only pretreated with TKIs and no prior immune therapy (NCT04567615).